• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CGF

CHALLENGER LIMITED - Charts / Financials

1.25% ! $8.68
Market Cap $6.001B  !
Financial Services Insurance - Life
Add to My Watchlist

Challenger Limited is an Australia-based investment management company. The Company... Challenger Limited is an Australia-based investment management company. The Company operates through two segments: Life and Funds Management. The Life segment principally includes the annuity and life insurance business carried out by Challenger Life Company (CLC). CLC offers fixed-rate and other retirement and superannuation products that are designed for Australian investors who are seeking a low-risk, fixed-term, or lifetime investment and reliable income. CLC also offers fixed-term and lifetime investments to investors in Japan through its reinsurance arrangement with Mitsui Sumitomo Primary Life Insurance Company Limited (MS Primary). CLC invests in assets that provide long-term income streams for customers. Its Funds Management segment is engaged in providing an end-to-end fund management business. The Funds Management segment also offers a range of managed investments across fixed income and property.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits
refresh Created with Sketch. REFRESH
Last update - 15.59pm 22/08/2025 (20 minute delay) ?
Day
Open $8.77   Day High $8.78   Day Low $8.62
Daily Volume 2774095
Bids   Sellers
Number Price Volume   Number Price Volume
2 $8.64 372   1 $8.70 17426

Directors & Senior Management

Mr. Nicolas Hamilton Chief Executive Officer, Managing Director, Executive Director
Ms. Alexandra Bell Chief Financial Officer
Mr. Anton Kapel Chief Executive - Life and Solutions
Mr. Victor Rodriguez Chief Executive officer of Funds Management
Ms. Linda Matthews Company Secretary
Mr. Duncan Gerald West Independent Non-Executive Chairman of the Board
Mr. Masahiko Kobayashi Non-Executive Director
Ms. Lisa J. Gray Independent Non-Executive Director
Mr. John M. Green Independent Non-Executive Director
Dr. Heather J. Smith Independent Non-Executive Director

Data source: Refinitiv

Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
$8.68 		Change
-0.110(1.25%) 		Mkt cap ! $6.001B
Open High Low Value Volume
$8.77 $8.78 $8.62 $24.08M 2.774M

Buyers (Bids)

No. Vol. Price($)
2 372 $8.64
 

Sellers (Offers)

Price($) Vol. No.
$8.70 17426 1
View Market Depth
Last trade - 16.12pm 22/08/2025 (20 minute delay) ?
Last
$8.67 		  Change
-0.110 ( 1.05 %)
Open High Low Volume
$8.78 $8.78 $8.63 337447
Last updated 15.59pm 22/08/2025 ?

Top Stories

Listen: HotCopper Wire Podcast 021 – The inexplicable Kaili Resources rocket

This week in the HotCopper Wire podcast we talk ASX earnings season, the +8,700% Kaili Resources rocket from Monday, and plenty more.
Inghams profits fall -10% YoY; cites challenging market and accounting rules Ingham’s Group (ASX:ING) was down -20% to around $2.80 in late morning Friday trades as the company’s NPAT fell -10% YoY. Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple,...
GYG down -20% as NPAT underwhelms; divvy not sweet enough, stock breaking even In a @Letter from the Co-CEOs” released by Guzman Y Gomez (ASX:GYG) along with its FY25 reports on Friday morning, one which reads painfully like a LinkedIn-influencer post, the company chiefs told investors the trillion-dollar global fast food industry is ready for disrupti...
Gold continuity at Asra's Orion, Sapphire 'not what was hoped' – but still lots to love Asra Minerals (ASX:ASR) has come away from diamond drilling at its Orion and Sapphire prospects at Leonora South a little disappointed.
Neurizon NUZ-001 OLE study demonstrates long-term safety, efficacy signals HotCopper sat down with Neurizon Therapeutics MD Michael Thurn to discuss the clinical-stage biotech company's latest NUZ-001 OLE study.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.